secwatch.observer — SEC 8-K summary
======================================

Issuer:     TCR2 THERAPEUTICS INC. (—)
CIK:        0001750019
Form:       8-K
Filed at:   2023-06-01T23:59:59+00:00
Accession:  0001104659-23-067031
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TCR2 completes merger with Adaptimmune; shareholders receive 1.5117 ADSs per share
--------------------------------------------------------------------------------

- Each TCR2 share exchanged for 1.5117 Adaptimmune ADSs; options and RSUs converted to Adaptimmune equity awards.
- TCR2 to delist from Nasdaq; plans to file Form 25 and Form 15 to suspend SEC reporting obligations.
- All directors resigned; Garry Menzel, Andrew Allen, Priti Hegde appointed to Adaptimmune board; Menzel resigned as TCR2 CEO.
- Fourth Amended and Restated Certificate of Incorporation and Second Amended and Restated By-Laws adopted.
- TCR2 becomes indirect wholly-owned subsidiary of Adaptimmune; change in control effective June 1, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750019/000110465923067031/0001104659-23-067031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750019/000110465923067031/tm2317482d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-067031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer